APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pituitary ACTH Hypersecretion Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pituitary ACTH Hypersecretion Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025198 pages

Choose your research edition.

Industry ResearchPituitary ACTH Hypersecretion Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pituitary ACTH Hypersecretion Drug Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Pituitary ACTH Hypersecretion Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pituitary ACTH Hypersecretion Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pituitary ACTH Hypersecretion Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pituitary ACTH Hypersecretion Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pituitary ACTH Hypersecretion Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pituitary ACTH Hypersecretion Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pituitary ACTH Hypersecretion Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pituitary ACTH Hypersecretion Drug include Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB, Cyclacel Pharmaceuticals, Inc., ElexoPharm GmbH, Ipsen S.A., Isis Pharmaceuticals, Inc., Orphagen Pharmaceuticals, Inc. and Pfizer Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pituitary ACTH Hypersecretion Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pituitary ACTH Hypersecretion Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pituitary ACTH Hypersecretion Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pituitary ACTH Hypersecretion Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pituitary ACTH Hypersecretion Drug Segment by Company

Alder Biopharmaceuticals Inc.

Corcept Therapeutics Incorporated

Cortendo AB

Cyclacel Pharmaceuticals, Inc.

ElexoPharm GmbH

Ipsen S.A.

Isis Pharmaceuticals, Inc.

Orphagen Pharmaceuticals, Inc.

Pfizer Inc.

Novartis AG

Pituitary ACTH Hypersecretion Drug Segment by Type

ISIS-GCCRRx

CORT-125134

COR-005

BIM-23A758

ATR-101

AT-814

Others

Pituitary ACTH Hypersecretion Drug Segment by Application

Clinic

Hospital

Others

Pituitary ACTH Hypersecretion Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pituitary ACTH Hypersecretion Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pituitary ACTH Hypersecretion Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pituitary ACTH Hypersecretion Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pituitary ACTH Hypersecretion Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pituitary ACTH Hypersecretion Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pituitary ACTH Hypersecretion Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pituitary ACTH Hypersecretion Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pituitary ACTH Hypersecretion Drug Industry Trends Table 2. Pituitary ACTH Hypersecretion Drug Industry Drivers Table 3. Pituitary ACTH Hypersecretion Drug Industry Opportunities and Challenges Table 4. Pituitary ACTH Hypersecretion Drug Industry Restraints Table 5. Global Pituitary ACTH Hypersecretion Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pituitary ACTH Hypersecretion Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Manufacturers Table 9. Global Pituitary ACTH Hypersecretion Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pituitary ACTH Hypersecretion Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pituitary ACTH Hypersecretion Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pituitary ACTH Hypersecretion Drug Manufacturers, Product Type & Application Table 13. Global Pituitary ACTH Hypersecretion Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pituitary ACTH Hypersecretion Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ISIS-GCCRRx Table 17. Major Manufacturers of CORT-125134 Table 18. Major Manufacturers of COR-005 Table 19. Major Manufacturers of BIM-23A758 Table 20. Major Manufacturers of ATR-101 Table 21. Major Manufacturers of AT-814 Table 22. Major Manufacturers of Others Table 23. Global Pituitary ACTH Hypersecretion Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021-2026) & (K Units) Table 25. Global Pituitary ACTH Hypersecretion Drug Sales by Type (2027-2032) & (K Units) Table 26. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2021-2026) Table 27. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2027-2032) Table 28. Global Pituitary ACTH Hypersecretion Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2021-2026) & (K Units) Table 30. Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2027-2032) & (K Units) Table 31. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2021-2026) Table 32. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Others Table 36. Global Pituitary ACTH Hypersecretion Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021-2026) & (K Units) Table 38. Global Pituitary ACTH Hypersecretion Drug Sales by Application (2027-2032) & (K Units) Table 39. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2021-2026) Table 40. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2027-2032) Table 41. Global Pituitary ACTH Hypersecretion Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2021-2026) & (K Units) Table 43. Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2027-2032) & (K Units) Table 44. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2021-2026) Table 45. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2027-2032) Table 46. Global Pituitary ACTH Hypersecretion Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Pituitary ACTH Hypersecretion Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Region (2021-2026) Table 49. Global Pituitary ACTH Hypersecretion Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Pituitary ACTH Hypersecretion Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 53. North America Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 54. Europe Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 56. Europe Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Pituitary ACTH Hypersecretion Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Pituitary ACTH Hypersecretion Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Pituitary ACTH Hypersecretion Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Region (2021-2026) Table 67. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Region (2027-2032) Table 68. Alder Biopharmaceuticals Inc. Company Information Table 69. Alder Biopharmaceuticals Inc. Business Overview Table 70. Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 72. Alder Biopharmaceuticals Inc. Recent Development Table 73. Corcept Therapeutics Incorporated Company Information Table 74. Corcept Therapeutics Incorporated Business Overview Table 75. Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Product Portfolio Table 77. Corcept Therapeutics Incorporated Recent Development Table 78. Cortendo AB Company Information Table 79. Cortendo AB Business Overview Table 80. Cortendo AB Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Cortendo AB Pituitary ACTH Hypersecretion Drug Product Portfolio Table 82. Cortendo AB Recent Development Table 83. Cyclacel Pharmaceuticals, Inc. Company Information Table 84. Cyclacel Pharmaceuticals, Inc. Business Overview Table 85. Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 87. Cyclacel Pharmaceuticals, Inc. Recent Development Table 88. ElexoPharm GmbH Company Information Table 89. ElexoPharm GmbH Business Overview Table 90. ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Product Portfolio Table 92. ElexoPharm GmbH Recent Development Table 93. Ipsen S.A. Company Information Table 94. Ipsen S.A. Business Overview Table 95. Ipsen S.A. Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Ipsen S.A. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 97. Ipsen S.A. Recent Development Table 98. Isis Pharmaceuticals, Inc. Company Information Table 99. Isis Pharmaceuticals, Inc. Business Overview Table 100. Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 102. Isis Pharmaceuticals, Inc. Recent Development Table 103. Orphagen Pharmaceuticals, Inc. Company Information Table 104. Orphagen Pharmaceuticals, Inc. Business Overview Table 105. Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 107. Orphagen Pharmaceuticals, Inc. Recent Development Table 108. Pfizer Inc. Company Information Table 109. Pfizer Inc. Business Overview Table 110. Pfizer Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Pfizer Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 112. Pfizer Inc. Recent Development Table 113. Novartis AG Company Information Table 114. Novartis AG Business Overview Table 115. Novartis AG Pituitary ACTH Hypersecretion Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Novartis AG Pituitary ACTH Hypersecretion Drug Product Portfolio Table 117. Novartis AG Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Pituitary ACTH Hypersecretion Drug Distributors List Table 121. Pituitary ACTH Hypersecretion Drug Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Pituitary ACTH Hypersecretion Drug Product Image Figure 2. Global Pituitary ACTH Hypersecretion Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pituitary ACTH Hypersecretion Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pituitary ACTH Hypersecretion Drug Sales (2021-2032) & (K Units) Figure 5. Global Pituitary ACTH Hypersecretion Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pituitary ACTH Hypersecretion Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ISIS-GCCRRx Image Figure 9. CORT-125134 Image Figure 10. COR-005 Image Figure 11. BIM-23A758 Image Figure 12. ATR-101 Image Figure 13. AT-814 Image Figure 14. Others Image Figure 15. Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Pituitary ACTH Hypersecretion Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2021-2032) Figure 18. Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Pituitary ACTH Hypersecretion Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2021-2032) Figure 27. Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 44. China Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Pituitary ACTH Hypersecretion Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Pituitary ACTH Hypersecretion Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Pituitary ACTH Hypersecretion Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Pituitary ACTH Hypersecretion Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Pituitary ACTH Hypersecretion Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Pituitary ACTH Hypersecretion Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Pituitary ACTH Hypersecretion Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • ISIS-GCCRRx
  • CORT-125134
  • COR-005
  • BIM-23A758
  • ATR-101
  • AT-814
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cortendo AB
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ipsen S.A.
  • Isis Pharmaceuticals, Inc.
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pituitary ACTH Hypersecretion Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pituitary ACTH Hypersecretion Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pituitary ACTH Hypersecretion Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pituitary ACTH Hypersecretion Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pituitary ACTH Hypersecretion Drug Market Dynamics
  1. 2.1 Pituitary ACTH Hypersecretion Drug Industry Trends
  2. 2.2 Pituitary ACTH Hypersecretion Drug Industry Drivers
  3. 2.3 Pituitary ACTH Hypersecretion Drug Industry Opportunities and Challenges
  4. 2.4 Pituitary ACTH Hypersecretion Drug Industry Restraints
3 Pituitary ACTH Hypersecretion Drug Market by Manufacturers
  1. 3.1 Global Pituitary ACTH Hypersecretion Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pituitary ACTH Hypersecretion Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pituitary ACTH Hypersecretion Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pituitary ACTH Hypersecretion Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pituitary ACTH Hypersecretion Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pituitary ACTH Hypersecretion Drug Manufacturers, Product Type & Application
  7. 3.7 Global Pituitary ACTH Hypersecretion Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pituitary ACTH Hypersecretion Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pituitary ACTH Hypersecretion Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pituitary ACTH Hypersecretion Drug Tier 1, Tier 2, and Tier 3
4 Pituitary ACTH Hypersecretion Drug Market by Type
  1. 4.1 Pituitary ACTH Hypersecretion Drug Type Introduction
  2. 4.1.1 ISIS-GCCRRx
  3. 4.1.2 CORT-125134
  4. 4.1.3 COR-005
  5. 4.1.4 BIM-23A758
  6. 4.1.5 ATR-101
  7. 4.1.6 AT-814
  8. 4.1.7 Others
  9. 4.2 Global Pituitary ACTH Hypersecretion Drug Sales by Type
  10. 4.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Pituitary ACTH Hypersecretion Drug Revenue by Type
  14. 4.3.1 Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2021-2032)
5 Pituitary ACTH Hypersecretion Drug Market by Application
  1. 5.1 Pituitary ACTH Hypersecretion Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Pituitary ACTH Hypersecretion Drug Sales by Application
  6. 5.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pituitary ACTH Hypersecretion Drug Revenue by Application
  10. 5.3.1 Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2021-2032)
6 Global Pituitary ACTH Hypersecretion Drug Sales by Region
  1. 6.1 Global Pituitary ACTH Hypersecretion Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pituitary ACTH Hypersecretion Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Pituitary ACTH Hypersecretion Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pituitary ACTH Hypersecretion Drug Revenue by Region
  1. 7.1 Global Pituitary ACTH Hypersecretion Drug Revenue by Region
  2. 7.1.1 Global Pituitary ACTH Hypersecretion Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Pituitary ACTH Hypersecretion Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pituitary ACTH Hypersecretion Drug Revenue (2021-2032)
  8. 7.2.2 North America Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pituitary ACTH Hypersecretion Drug Revenue (2021-2032)
  11. 7.3.2 Europe Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pituitary ACTH Hypersecretion Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alder Biopharmaceuticals Inc.
  2. 8.1.1 Alder Biopharmaceuticals Inc. Company Information
  3. 8.1.2 Alder Biopharmaceuticals Inc. Business Overview
  4. 8.1.3 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  6. 8.1.5 Alder Biopharmaceuticals Inc. Recent Developments
  7. 8.2 Corcept Therapeutics Incorporated
  8. 8.2.1 Corcept Therapeutics Incorporated Company Information
  9. 8.2.2 Corcept Therapeutics Incorporated Business Overview
  10. 8.2.3 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Product Portfolio
  12. 8.2.5 Corcept Therapeutics Incorporated Recent Developments
  13. 8.3 Cortendo AB
  14. 8.3.1 Cortendo AB Company Information
  15. 8.3.2 Cortendo AB Business Overview
  16. 8.3.3 Cortendo AB Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cortendo AB Pituitary ACTH Hypersecretion Drug Product Portfolio
  18. 8.3.5 Cortendo AB Recent Developments
  19. 8.4 Cyclacel Pharmaceuticals, Inc.
  20. 8.4.1 Cyclacel Pharmaceuticals, Inc. Company Information
  21. 8.4.2 Cyclacel Pharmaceuticals, Inc. Business Overview
  22. 8.4.3 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  24. 8.4.5 Cyclacel Pharmaceuticals, Inc. Recent Developments
  25. 8.5 ElexoPharm GmbH
  26. 8.5.1 ElexoPharm GmbH Company Information
  27. 8.5.2 ElexoPharm GmbH Business Overview
  28. 8.5.3 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Product Portfolio
  30. 8.5.5 ElexoPharm GmbH Recent Developments
  31. 8.6 Ipsen S.A.
  32. 8.6.1 Ipsen S.A. Company Information
  33. 8.6.2 Ipsen S.A. Business Overview
  34. 8.6.3 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Product Portfolio
  36. 8.6.5 Ipsen S.A. Recent Developments
  37. 8.7 Isis Pharmaceuticals, Inc.
  38. 8.7.1 Isis Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Isis Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  42. 8.7.5 Isis Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Orphagen Pharmaceuticals, Inc.
  44. 8.8.1 Orphagen Pharmaceuticals, Inc. Company Information
  45. 8.8.2 Orphagen Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  48. 8.8.5 Orphagen Pharmaceuticals, Inc. Recent Developments
  49. 8.9 Pfizer Inc.
  50. 8.9.1 Pfizer Inc. Company Information
  51. 8.9.2 Pfizer Inc. Business Overview
  52. 8.9.3 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  54. 8.9.5 Pfizer Inc. Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Pituitary ACTH Hypersecretion Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Pituitary ACTH Hypersecretion Drug Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pituitary ACTH Hypersecretion Drug Value Chain Analysis
  2. 9.1.1 Pituitary ACTH Hypersecretion Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pituitary ACTH Hypersecretion Drug Production Mode & Process
  6. 9.2 Pituitary ACTH Hypersecretion Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pituitary ACTH Hypersecretion Drug Distributors
  9. 9.2.3 Pituitary ACTH Hypersecretion Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst